Don’t Miss These Cleveland Clinic Cancer Center Presentations at the 2019 ASCO Annual Meeting

Friday, May 31

1-2 p.m.
E451
INTERACTIVE CASE-BASED SESSION:
Do We Know How to Use Hypomethylating Agents in Myeloid Disorders?
What Is the Right Decitabine Treatment Duration?
Mikkael A. Sekeres, MD, MS — Speaker

2:45-3:00 p.m.
Hall D1
EDUCATION SESSION:
Real-World Tumor/Plasma Genetic Testing: Tough Choices, How Do You Pick?
Guidelines, Barriers, Access to Molecular Testing in NSCLC
Nathan A. Pennell, MD, PhD — Chair

3:25-3:45 p.m.
S100bc
EDUCATION SESSION:
On the Shoulders of Giants: Past, Present, and Future of Systemic Therapy for Lung Cancer
The Next Frontier: Understanding and Overcoming Resistance to Targeted Therapy and Immunotherapy
Pradnya Dinkar Patil, MD, FACP — Speaker

Saturday, June 1

8-11 a.m.
Hall A
POSTER SESSIONS:
Clonal Expansion of Tumor Infiltrating Lymphocytes (TILs) in the Peripheral Blood of Metastatic Melanoma Patients Is Significantly Associated with Response to CTLA4 Blockade-Based ImmunotherapyPoster Board: #185; Abstract 2541
Arjun Khunger, MD — First Author

Intra and Perinodular CT Delta Radiomic Features Associated with Early Response to Predict Overall Survival (OS) in Immunotherapy-Treated Non-Small Cell Lung Cancer (NSCLC): A Multisite Multi-Agent Study

Poster Board: #232; Abstract 2588

Pradnya Dinkar Patil, MD, FACP — Author

1:15-4:15 p.m.
Hall A
POSTER SESSIONS:
Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration
Poster Board: #69; Abstract 6080
Jessica Lyn Geiger, MD — First Author

Development of a Financial Navigation Program to Ease the Burden of Financial Toxicity
Poster Board: #256; Abstract 6565
Melissa Monak, CPC — First Author

Virtual Visits for Children, Adolescents, and Young Adults with Cancer
Poster Board: #313; Abstract 6622
Peter Meade Anderson, MD, PhD — First Author

Long-Term Survival of Adjuvant High-Dose (HDC) vs Weekly Cisplatin (WC) for Human Papilloma-Virus (HPV) and Non-HPV Head and Neck Squamous Cell Carcinoma (HNSCC)
Poster Board: #60; Abstract 6071
Jessica Lyn Geiger, MD — Author

Phase 2 Trial of Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer (innovaTV 208)
Poster Board: #421a; Abstract TPS5602
Haider Mahdi, MD — First Author

Improving Time to Initiation of Bone Modifying Agents in Patients with Newly Diagnosed Multiple Myeloma
Poster Board: #219; Abstract 6528
Nathaniel Rosko, BCOP, PharmD — First Author

Implications of the United States Preventive Services Task Force (USPSTF) Recommendations on Prostate Cancer (PCa) Stage Migration
Poster Board: #183; Abstract 5071
Iris Yeong-Fung Sheng, MD — First Author

Accelerating Advanced Precision Medicine Through a Harmonized Data Exchange Platform and Research Consortium (PMEC)
Poster Board: #248; Abstract 6557
Davendra Sohal, MD, MPH — First Author

HSD3B1 and Overall Survival (OS) in Men with Low-Volume (LV) Metastatic Prostate Cancer (PCa) Treated with Androgen Deprivation Therapy (ADT) or Chemohormonal Therapy in the CHAARTED Randomized Trial
Poster Board: #132; Abstract 5020
Nima Sharifi, MD — Author

Sunday, June 2

8-11 a.m.
Hall A
POSTER SESSIONS:
SurVaxM with Standard Therapy in Newly Diagnosed Glioblastoma: Phase II Trial Update
Poster Board: #205; Abstract 2016
Manmeet Singh Ahluwalia, MD, FACP — First Author

Updated Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM
Poster Board: #206; Abstract 2017
Manmeet Singh Ahluwalia, MD, FACP — Author

Safety and Activity of a First-in-Class Oral HIF2-Alpha Inhibitor, PT2385, in Patients with First Recurrent Glioblastoma (GBM)
Poster Board: #216; Abstract 2027
Manmeet Singh Ahluwalia, MD, FACP — Author

Patterns of Systemic Treatment Utilization in ER+/PgR+/HER2+, Early-Stage Breast Cancer (BC): An Analysis of the National Cancer Database
Poster Board: #39; Abstract 547
Zeina A. Nahleh, MD — First Author

Disparities in Treatment Patterns and Overall Survival (OS) in Hormone Receptor-Positive HER2+ Metastatic Breast Cancer (MBC): A National Cancer Database Analysis
Poster Board: #113; Abstract 1032
Abby Statler, MA, MPH, PhD — First Author

Real-World Treatment Patterns and Outcomes in ER+/PR+/HER2+ Metastatic Breast Cancer (MBC) Patients: A National Cancer Database Analysis
Poster Board: #114; Abstract 1033
Abby Statler, MA, MPH, PhD — First Author

Clinical Characteristics and Outcome of Metaplastic Breast Cancer: A Retrospective Tertiary Care Center Experience
Poster Board: #176; Abstract 1095
Bicky Thapa, MD — First Author

Development and External Validation of a Deep Learning Model for Predicting Response to HER2-Targeted Neoadjuvant Therapy from Pretreatment Breast MRI
Poster Board: #85; Abstract 593
Manasa Vulchi, MBBS — First Author

Monday, June 3

8-11 a.m.
Hall A
POSTER SESSIONS:
SWOG S1505: Initial Findings on Eligibility and Neoadjuvant Chemotherapy Experience with mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Poster Board: #242; Abstract 4137
Davendra Sohal, MD, MPH — First Author

Response to Brentuximab Vedotin by CD30 Expression: Results from Five Trials in PTCL, CTCL, and B-cell Lymphomas
Poster Board: #297; Abstract 7543
Deepa Jagadeesh, MD, MPH — First Author

Rivaroxaban Thromboprohylaxis in Ambulatory Patients with Pancreatic Cancer: Results from a Prespecified Subgroup Analysis of the CASSINI Study
Poster Board: #121; Abstract 4016
Alok Khorana MD — Author

Outcomes in Large B-cell Lymphoma Progressing After Axicabtagene Ciloleucel (Axi-cel): Results from the U.S. Lymphoma CAR-T Consortium

Poster Board: #271; Abstract 7517

Brian Thomas Hill, MD, PhD — Author

Low-Dose Cytarabine with or without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial

Poster Board: #385; Abstract 7010

Mikkael A. Sekeres, MD, MS — Author

Improved Overall Survival (OS) for Advanced Pancreatic Cancer (PDAC) Patients (pts) Enrolled in the Know Your Tumor (KYT) Program Whose Tumors Harbored Highly Actionable Molecular Alterations and Who Received Molecularly-Matched Therapies (tx)

Poster Board: #243; Abstract 4138

Davendra Sohal, MD, MPH — Author

8:00-8:12 a.m.
Arie Crown Theater

ORAL ABSTRACT SESSION:

Genitourinary (Nonprostate) Cancer
Pembrolizumab (pembro) Plus Axitinib (axi) versus Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma (mRCC): Outcomes in the Combined IMDC Intermediate/Poor Risk and Sarcomatoid Subgroups of the Phase 3 KEYNOTE-426 study

Abstract 4500

Brian I. Rini, MD, FACP — First Author

8:00-8:20 a.m.
S504
EDUCATION SESSION:

Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges
Ethical Care Practices: Respecting Cultural and Societal Differences to Safeguard the Therapeutic Relationship
Eric Kodish, MD — Chair

10:00-10:15 a.m.
E451
EDUCATION SESSION:

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?
To Radiate or Not to Radiate: Nuances of Radiation Therapy for Low-Grade Gliomas
Jennifer S. Yu, MD, PhD — Chair

11:30 a.m.-12:30 p.m.
E451
INTERACTIVE CASE-BASED SESSION:

Emerging New Standards of Care for Advanced Kidney Cancer
Is There a Role for Active Surveillance or Focal Approaches in Advanced Renal Cell Carcinoma?

Brian I. Rini, MD, FACP — Speaker

1:15-2:15 p.m.
Hall D2
INTERACTIVE CASE-BASED SESSION:

Controversies in Breast Cancer Adjuvant Therapy
Case 1. Managing Residual ER-Negative Disease after Neoadjuvant Chemotherapy
Alberto J. Montero, MD, MBA — Speaker

1:15-4:15 p.m.
S102
ORAL ABSTRACT SESSION:

Central Nervous System Tumors
Activity of Larotrectinib in TRK Fusion Cancer Patients with Brain Metastases or Primary Central Nervous System Tumors

Abstract 2006
Davendra Sohal, MD, MPH — Author

1:15-4:15 p.m.
Hall A
POSTER SESSIONS:
KEYNOTE-630: Phase 3 Study of Adjuvant Pembrolizumab versus Placebo in Patients with High-Risk, Locally Advanced Cutaneous Squamous Cell Carcinoma
Poster Board: #166b; Abstract TPS9597
Jessica Lyn Geiger, MD — First Author

Improve: A Community-Based Physical Activity Intervention to Improve Functional and Health Outcomes in Older Breast Cancer Survivors: Rationale, Design and Methods
Poster Board: #321a; Abstract TPS11629
Madison Conces, MD — First Author

Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations in Solid Tumor Malignancies
Poster Board: #1; Abstract 1507
Madison Conces, MD — First Author

Circulating Cell-Free DNA (cfDNA) Levels and Fragmentation Pattern Can Distinguish Nonmuscle Invasive (NMI) from Muscle-Invasive (MI) and Metastatic (met) Bladder Cancer (BC)
Poster Board: #349; Abstract 4523
Jaleh Fallah, MD — First Author

Association of Cell-Free DNA (cfDNA) Levels with Myeloid-Derived Suppressor Cells (MDSC) Levels in Blood of Patients (pts) with Muscle Invasive (MI) and Metastatic (met) Bladder Cancer (BC)
Poster Board: #354; Abstract 4528
Jaleh Fallah, MD — First Author

Atezolizumab (atezo) + Bevacizumab (bev) versus Sunitinib (sun) in Pts with Untreated Metastatic Renal Cell Carcinoma (mRCC) and Sarcomatoid (sarc) Histology: IMmotion151 Subgroup Analysis
Poster Board: #338; Abstract 4512
Brian I. Rini, MD, FACP — First Author

CheckMate 214 Post-Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features
Poster Board: #339; Abstract 4513
Brian I. Rini, MD, FACP — Author

Patient-Reported Outcomes (PROs) in IMmotion150: Atezolizumab (atezo) Alone or with Bevacizumab (bev) versus Sunitinib (sun) in First-Line Metastatic Renal Cell Carcinoma (mRCC)
Poster Board: #345; Abstract 4515
Brian I. Rini, MD, FACP — Author

TIVO-3: Subgroup Analysis of Progression-Free Survival of Tivozanib Compared to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC)
Poster Board: #398; Abstract 4572
Brian I. Rini, MD, FACP — Author

Consistent Efficacy of Nivolumab Plus Ipilimumab Across Number of International Metastatic Database Consortium (IMDC) Risk Factors in CheckMate 214
Poster Board: #401; Abstract 4575
Brian I. Rini, MD, FACP — Author

Systemic Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC) After Progression on Immune-Oncology plus VEGF Targeted Therapy Combinations (IO-VEGF)
Poster Board: #402; Abstract 4576
Brian I. Rini, MD, FACP — Author

Deferred Cytoreductive Nephrectomy Among Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma Treated Initially with Sunitinib
Poster Board: #404; Abstract 4578
Brian I. Rini, MD, FACP — Author

Tuesday, June 4

8:45-9:00 a.m.
E451
EDUCATION SESSION:

Point/Counterpoint: Duration of Therapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia
Maintenance After Frontline Therapy in Follicular Lymphoma? An Appropriate Management Plan for Selected Patients
Brian Thomas Hill, MD, PhD — Speaker